度洛西汀合并氨磺必利治疗躯体症状为主的抑郁症对照研究  

Comparative study of amisulpride combined with duloxetine in the treatment of depression with predominant somatic complains

作　　者：王晓枫[1] 韦有芳[1] 王丽丽[1] 

机构地区：[1]山东省临沂市精神卫生中心,276005

出　　处：《精神医学杂志》2015年第1期46-48,共3页Journal of Psychiatry

摘　　要：目的探讨度洛西汀合并氨磺必利治疗以躯体症状为主的抑郁症的疗效及安全性。方法将以躯体症状为主的抑郁症患者60例随机分为度洛西汀合并氨磺必利治疗组30例(研究组)和度洛西汀治疗组30例(对照组)。于治疗前及治疗后第2、4、6、8周末采用汉密尔顿抑郁量表(HAMD)、症状自评量表(SCL-90)躯体化因子分、治疗中需处理的不良反应量表(TESS)进行疗效及不良反应评定。结果两组治疗后第2、4、6、8周末HAMD和SCL-90躯体化因子评分较治疗前下降(P<0.05)。在治疗后第2周末起,研究组HAMD和SCL-90躯体化因子评分均低于对照组(P<0.05),两组总体不良反应发生率比较无显著性差异(P>0.05),但研究组肝功能异常、闭经、体质量增加不良反应发生率高于对照组(P<0.05)。结论度洛西汀合并氨磺必利治疗躯体症状为主的抑郁症疗效优于单用度洛西汀。Objective To explore the efficacy and safety of amisulpride combined with duloxetine in the treatment of depression with predominant somatic complains.Methods 60 depressive patients with predominant somatic complains were randomized into study group （30 cases）treated with amisulpride combined duloxetine and control group （30 cases）treated with duloxetine monotherapy for 8 weeks.All patients were assessed with Hamilton Depression Scale （HAMD）,the somatization item of SCL-90 and Treatment Emergent Symptom Scale （TESS）at baseline and at the end of the 2nd ,4th ,6 th ,8th week of treatment to evaluate the efficacy and side effects.Results Compared with the baseline,score of HAMD and factor score of somatization item of SCL-90 in both groups decreased significantly at the end of the 2nd ,4th ,6 th ,8th week of treatment （P 〈0.05）.From the 2nd week of the treatment,scores of HAMD and factor scores of somatization item of SCL-90 in study group were significantly lower than those in control group （P 〈0.05）.There was no significant difference in overall incidence rate of side effects between the two groups （P〉0.05）,but the incidence rate of liver dysfunction,menostasis and weight gain were significantly higher in study group than in control group （P 〈0.05 ）.Conclusion Amisulpride combined with duloxetine has better efficacy than duloxetine monotherapy in the treatment of depression with predominant somatic complains.

关 键 词：度洛西汀 氨磺比利 抑郁症 躯体症状 

分 类 号：R749.4[医药卫生—神经病学与精神病学]